HUMA250321P00002000 Option on Humacyte

HUMA Stock  USD 3.43  0.39  12.83%   
HUMA250321P00002000 is a PUT option contract on Humacyte's common stock with a strick price of 2.0 expiring on 2025-03-21. The contract was not traded in recent days and, as of today, has 21 days remaining before the expiration. The option is currently trading at an ask price of $0.5. The implied volatility as of the 28th of February is 21.0.
  
A put option written on Humacyte becomes more valuable as the price of Humacyte drops. Conversely, Humacyte's put option loses its value as Humacyte Stock rises.

Rule 16 of 2025-03-21 Option Contract

The options market is anticipating that Humacyte will have an average daily up or down price movement of about 0.18% per day over the life of the option. With Humacyte trading at USD 3.43, that is roughly USD 0.006344. If you think that the market is fully understating Humacyte's daily price movement you should consider buying Humacyte options at that current volatility level of 2.96%. But if you have an opposite viewpoint you should avoid it and even consider selling them.

Out Of The Money Put Option on Humacyte

An 'Out of The Money' option on Humacyte has a strike price that Humacyte Stock has yet to reach, meaning the option has no intrinsic value. 'Out of The Money' options are usually less costly than 'In The Money' options, making them more desirable to traders with smaller amounts of capital. Some of the uses for Humacyte's 'Out of The Money' options include buying the options if you expect a big move in Humacyte's stock. Since 'Out of The Money' options have a lower up-front cost (i.e., no intrinsic value) than 'In The Money' options, buying it is a reasonable choice.
Put Contract NameHUMA250321P00002000
Expires On2025-03-21
Days Before Expriration21
Vega0.001833
Gamma0.090519
Theoretical Value0.25
Open Interest166
Strike Price2.0
Last Traded At0.03
Current Price Spread0.0 | 0.5
Rule 16 Daily Up or DownUSD 0.006344

Humacyte short PUT Option Greeks

Humacyte's Option Greeks for the contract ending on 2025-03-21 at a strike price of 2.0 measures the various factors that affect its cost and calculated using a theoretical options pricing model. It helps investors make more informed decisions about whether to trade this option contract or when to trade it. In addition to Humacyte's option greeks, its implied volatility helps estimate the risk of Humacyte stock implied by the prices of the options on Humacyte's stock.
Delta-0.139044
Gamma0.090519
Theta-0.012251
Vega0.001833
Rho-3.9E-4

Humacyte long PUT Option Payoff at expiration

Put options written on Humacyte grant holders of the option the right to sell a specified amount of Humacyte at a specified price within a specified time frame. The put buyer has a limited loss and, while not fully unlimited gains, as the price of Humacyte Stock cannot fall below zero, the put buyer does gain as the price drops. So, purchasing a put option on Humacyte is like buying insurance aginst Humacyte's downside shift.
   Profit   
Break Even 1.75Strike Price 2Strike Price 2Current Price 3.43100%
       Humacyte Price At Expiration  

Humacyte short PUT Option Payoff at expiration

By selling Humacyte's put option, the investors signal their bearish sentiment. A short position in a put option written on Humacyte will generally make money when the underlying price is above the strike price. Therefore Humacyte's put payoff at expiration depends on where the Humacyte Stock price is relative to the put option strike price. The breakeven price of 1.75 is the critical point that divides the payoff function into two parts. Below the breakeven price, the payoff is dropping and negative (the seller makes a loss). Above the breakeven price, the payoff line is upward sloping as the option payoff increases in proportion to Humacyte's price. Finally, at the strike price of 2.0, the payoff chart is constant and positive.
   Profit   
       Humacyte Price At Expiration  
View All Humacyte Options

Humacyte Available Put Options

Humacyte's option chain is a display of a range of information that helps investors for ways to trade options on Humacyte. In general, an option chain provides a helpful tool for investors to see all available option contracts, both puts, and calls, for Humacyte. It also shows strike prices and maturity days for a Humacyte against a given expiration period. The table below combines all the option information in the form of a chain but before you use it, remember that it entails significant risk and it is not for everyone.
Open IntStrike PriceCurrent SpreadLast Price
 Put
HUMA250417P0000150001.50.0 - 0.50.5Out
 Put
HUMA250417P00003500463.50.0 - 0.80.3In
 Put
HUMA250417P00003000703.00.2 - 0.60.2Out
 Put
HUMA250417P0000250002.50.0 - 0.20.2Out
 Put
HUMA250417P0000200002.00.0 - 0.10.1Out
 Put
HUMA250417P0000550085.50.0 - 2.452.2In
 Put
HUMA250417P0000500005.00.0 - 1.951.95In
 Put
HUMA250417P0000450014.50.0 - 1.551.15In
 Put
HUMA250417P0000400024.00.0 - 1.00.67In
 Put
HUMA250417P0000750007.53.9 - 5.03.9In

Humacyte Corporate Management

Harold AltersonSenior QualityProfile
Sabrina OsborneExecutive PeopleProfile
Dale SanderChief CFOProfile
William ScheesseleChief OfficerProfile
Yang MDChief OfficerProfile
Shamik MDChief OfficerProfile
When determining whether Humacyte is a strong investment it is important to analyze Humacyte's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Humacyte's future performance. For an informed investment choice regarding Humacyte Stock, refer to the following important reports:
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Humacyte. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.
For information on how to trade Humacyte Stock refer to our How to Trade Humacyte Stock guide.
You can also try the Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Humacyte. If investors know Humacyte will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Humacyte listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.34)
Quarterly Revenue Growth
(1.00)
Return On Assets
(0.53)
Return On Equity
(8.51)
The market value of Humacyte is measured differently than its book value, which is the value of Humacyte that is recorded on the company's balance sheet. Investors also form their own opinion of Humacyte's value that differs from its market value or its book value, called intrinsic value, which is Humacyte's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Humacyte's market value can be influenced by many factors that don't directly affect Humacyte's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Humacyte's value and its price as these two are different measures arrived at by different means. Investors typically determine if Humacyte is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Humacyte's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
News Freq…Investor S…